Search clinical trials for: Docetaxel combined with Trastuzumab±Pertuzumab
Total 1596 results
-
Fudan UniversityRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingHER2-positive Metastatic Breast Cancer | Previously Treated With Trastuzumab | Trastuzumab Combined With Pertuzumab and ChemotherapyChina
-
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.LtdUnknown
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedNon Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage IIIFrance
-
Peking University People's HospitalRecruitingHER2-positive Early Breast CancerChina
-
Thomas HatschekActive, not recruitingEarly-Stage Breast Carcinoma | HER-2 Positive Breast CancerSweden
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingHER2-PositiveRecurrent or Metastatic Breast Cancer
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | NeratiniChina
-
Hoffmann-La RocheGenentech, Inc.CompletedBreast CancerUnited States, Italy, United Kingdom, Australia, Austria, Belgium, Brazil, Denmark, France, Guatemala, Korea, Republic of, Portugal, Spain, Turkey, Colombia, Canada, Czechia, Japan, Poland, Romania, Russian Federation, Switzerland, ... and more
-
European Organisation for Research and Treatment...Hoffmann-La RocheCompletedElderly Metastatic Breast Cancer PopulationBelgium, Italy, Netherlands, France, Poland, United Kingdom, Portugal, Sweden
-
Henan Cancer HospitalRecruitingBreast Cancer | HER2-positive Breast CancerChina
-
Shengjing HospitalNot yet recruiting
-
Fudan UniversityCompleted
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
Hoffmann-La RocheCompletedBreast CancerHungary, Italy, Spain, France, United Kingdom, Belgium, Germany, Portugal, Poland, Canada, Bulgaria, Mexico
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Completed
-
Hoffmann-La RocheCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Roche Pharma AGCompletedEsophageal CarcinomaNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Active, not recruiting
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingHER2-positive Breast CancerChina
-
Henan Cancer HospitalRecruitingBreast Cancer,Her2 PositiveChina
-
Hospices Civils de LyonNot yet recruiting
-
Guangdong Provincial People's HospitalRecruitingNeoadjuvant Therapies for HER2+ Breast CancerChina
-
Hoffmann-La RocheCompletedHER2-Positive Early Breast CancerUnited States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
-
Fujian Medical University Union HospitalRecruiting
-
Henan Cancer HospitalWithdrawnBreast Cancer | HER2-positive Breast CancerChina
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, Turkey, United Kingdom, Kenya, Hungary, Poland, Colombia, India, Oman, Uganda, United Arab... and more
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingA Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BCHER2-positive Breast CancerChina
-
Genentech, Inc.Approved for marketing
-
Memorial Sloan Kettering Cancer CenterUnited States Department of Defense; Genentech, Inc.CompletedBreast Cancer Metastases | HER2 Positive BreastUnited States
-
The Second Affiliated Hospital of Shandong First...Recruiting
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawnBreast CancerUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBreast CancerUnited States
-
Fundacio Clinic BarcelonaRoche Pharma AG; SOLTI Breast Cancer Research GroupRecruitingStage I Breast Cancer | HER2-positive Breast CancerSpain
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; Genentech, Inc.CompletedBreast CancerUnited States
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
Gruppo Oncologico Italiano di Ricerca ClinicaMipharm SpA; Temas srl; Clirest s.r.l.; University Hospital of Parma: Department... and other collaboratorsUnknown
-
Peking UniversityRecruitingHER2-positive Breast CancerChina
-
AgendiaUniversity of South Florida; University of Miami; University of Oklahoma; Ohio... and other collaboratorsCompletedBreast CancerUnited States
-
Hoffmann-La RocheActive, not recruitingInflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast CancerCanada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
-
Jules Bordet InstituteHoffmann-La Roche; Breast International Group; Institut Curie; International Drug...SuspendedHER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast CancerKorea, Republic of, France, Israel, Belgium, Switzerland, Australia
-
National Cancer Institute (NCI)TerminatedAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast CarcinomaUnited States
-
Xuekui LiuNot yet recruiting
-
Hoffmann-La RocheCompletedBreast CancerItaly, Korea, Republic of, Spain, Taiwan, United Kingdom, Brazil, Russian Federation, Thailand, Israel, Turkey, Austria, Canada, Poland, Sweden, Australia, Peru, Switzerland, Mexico
-
Institut für Klinische Krebsforschung IKF GmbH...Trium Analysis Online GmbHCompletedStomach Cancer | Gastroesophageal Junction CancerGermany
-
National Cancer Institute (NCI)Active, not recruitingMalignant Solid NeoplasmUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingMetastatic Breast CancerChina
-
Shanghai JMT-Bio Inc.Not yet recruitingFirst-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
-
Qamar KhanRecruitingHER2-positive Breast CancerUnited States
-
Shandong Cancer Hospital and InstituteNot yet recruiting